NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
Details of the oral presentation are as follows:
Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression
Session Type: In-Person Oral Presentation
Session Title: Novel Production Platforms
Abstract Number: 282
Location: Ballroom 2
Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET
Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Meru Advisors
Lee M. Stern
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.14 |
| Daily Change: | -0.02 -11.99 |
| Daily Volume: | 12,407,076 |
| Market Cap: | US$9.780M |
June 02, 2025 April 29, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
